Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development

September 10, 2019

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), today announced the appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development.
More »

Milestone Pharmaceuticals Provides Positive Regulatory Updates for Etripamil Pivotal Program in PSVT and Reports Second Quarter 2019 Financial Results

August 13, 2019

FDA agrees to allow initiation of NODE-303 open-label safety study without test dose and in population consistent with ongoing studies
More »

WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer

June 25, 2019

WindMIL Therapeutics announced today that it has been cleared by the U.S. Food and Drug Administration (FDA) to proceed with its Phase 2 study of MILs as a potential treatment for patients with non-small cell lung cancer (NSCLC)
More »